SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline...
Read More Details
Finally We wish PressBee provided you with enough information of ( Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients )
Also on site :
- Beloved brand ends controversial 50 cent fee on popular breakfast staple as it gets ahead of Waffle House
- Wimbledon: Naomi Osaka loses to Anastasia Pavlyuchenkova in the 3rd round
- Should You Expect USPS Mail Delivery on July 4th?